Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 5/20 | 0.48 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | TTK | P33981 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | STK25 | O00506 | 1/20 | 0.48 |
| ▸ | CIT | O14578 | 1/20 | 0.48 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.48 |
| ▸ | CHUK | O15111 | 1/20 | 0.48 |
| ▸ | MUSK | O15146 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945140 | 1.00 | CHEK1 (0.48) | CHEK1KDRMAP2K4AURKAFLT3 | |
| SCHEMBL2570808 | 0.85 | KDR (0.47) | CHEK1KDRMAP2K4AURKAFLT3 | |
| SCHEMBL13924410 | 0.81 | KDM4E (0.54) | CHEK1KDRMAP2K4AURKAFLT3 | |
| SCHEMBL2132768 | 0.81 | KDM4E (0.54) | CHEK1KDRMAP2K4AURKAFLT3 | |
| SCHEMBL3131646 | 0.81 | KDM4E (0.54) | CHEK1KDRMAP2K4AURKAFLT3 | |
| SCHEMBL4197352 | 0.80 | MMP1 (0.57) | AURKAITKKDM4EALDH1A1MAPK1 | |
| SCHEMBL4197357 | 0.80 | MMP1 (0.57) | AURKAITKKDM4EALDH1A1MAPK1 | |
| SCHEMBL12311266 | 0.80 | CHEK1 (0.40) | CHEK1KDRTTKCDK4CCNA2 | |
| SCHEMBL22130476 | 0.79 | LMNA (0.56) | CHEK1KDRAURKAFLT3CDK4 | |
| SCHEMBL10324487 | 0.79 | CHEK1 (0.44) | CHEK1KDRMAP2K4AURKAFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632899-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RaQualia Pharma Inc. (JP) | 2020-04-08 | — | — | EP | disclosed |
| EP-2435407-B1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2019-12-25 | — | — | EP | disclosed |
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| JP-2013216579-A | METHOD FOR PRODUCING TRISUBSTITUTED INDAZOLEACRYLAMIDE DERIVATIVE | MITSUBISHI TANABE PHARMA CORP | 2013-10-24 | — | — | JP | disclosed |
| WO-2012005312-A1 | PROCESS FOR PREPARATION OF TRISUBSTITUTED INDAZOLEACRYLAMIDE DERIVATIVES | 田辺三菱製薬株式会社 (JP) | 2012-01-12 | — | — | WO | disclosed |
| US-8022059-B2 | Indazole acrylic acid amide compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022059-B2 | Indazole acrylic acid amide compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-20 | — | — | US | disclosed |
| WO-2010137351-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2010-12-02 | — | — | WO | disclosed |
| US-20100256108-A1 | INDAZOLE ACRYLIC ACID AMIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256108-A1 | INDAZOLE ACRYLIC ACID AMIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2192116-A1 | INDAZOLE ACRYLIC ACID AMIDE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-06-02 | — | — | EP | disclosed |
| EP-1648448-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080058515-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-20080058515-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-20080058515-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-03-06 | — | — | US | disclosed |
| EP-1648448-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005011681-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | CHEK1 4568/4885KDR 3745/4885MAP2K4 4236/4885 |
| US-20080058515-A1 | Chemical Compounds | SGK1, SGK2, SGK3 | CHEK1 113/4885KDR 4133/4885MAP2K4 559/4885 |
| US-20100256108-A1 | INDAZOLE ACRYLIC ACID AMIDE COMPOUND | KCNH2, KCNH3, KCNJ11 | CHEK1 2605/4885KDR 2531/4885MAP2K4 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.